RP1

About Replimune

Replimune is a clinical-stage biotech with a mission to revolutionize cancer treatment through comprehensive activation of tumor-specific immune responses. The company's core achievement is the development of its proprietary RPx platform, a next-generation, engineered HSV-1-based oncolytic immunotherapy, which is now in late-stage clinical trials. Its strategy focuses on advancing a pipeline of wholly-owned assets across solid tumors, with a lead program (RP1) in advanced melanoma under regulatory review (PDUFA July 22, 2025), supported by in-house manufacturing and key commercial partnerships.

About Replimune

Replimune is a clinical-stage biotech with a mission to revolutionize cancer treatment through comprehensive activation of tumor-specific immune responses. The company's core achievement is the development of its proprietary RPx platform, a next-generation, engineered HSV-1-based oncolytic immunotherapy, which is now in late-stage clinical trials. Its strategy focuses on advancing a pipeline of wholly-owned assets across solid tumors, with a lead program (RP1) in advanced melanoma under regulatory review (PDUFA July 22, 2025), supported by in-house manufacturing and key commercial partnerships.

About Replimune

Replimune is a clinical-stage biotech with a mission to revolutionize cancer treatment through comprehensive activation of tumor-specific immune responses. The company's core achievement is the development of its proprietary RPx platform, a next-generation, engineered HSV-1-based oncolytic immunotherapy, which is now in late-stage clinical trials. Its strategy focuses on advancing a pipeline of wholly-owned assets across solid tumors, with a lead program (RP1) in advanced melanoma under regulatory review (PDUFA July 22, 2025), supported by in-house manufacturing and key commercial partnerships.

Therapeutic Areas

Other Advanced Melanoma Drugs